2109805-56-1

CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC50s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity[1].

T3-CLK (T3) is a cell permeablehighly potent and selective cell-base stable inhibitor of CDC-like kinase (CLK) th at exhibits dose-dependent alternative splicing effects in HCT116 colorectal cancer cells. T3-CLK increases conjoined gene (CG) transcription.

CLK1: 0.67 nM (IC₅₀); CLK2: 15 nM (IC₅₀); CLK3: 110 nM (IC₅₀); DYRK1A: 260 nM (IC₅₀); DYRK1B: 230 nM (IC₅₀)

[1] Funnell T, et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel smallmolecule inhibitor. Nat Commun. 2017 Feb 23;8(1):7. DOI:10.1038/s41467-016-0008-7